Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FENOMENO study of BDP/formoterol reliever effects on exhaled nitric oxide in asthma
2007-004377-26Phase 2Terminated
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of beclometasone dipropionate + formoterol and salbutamol in asthma (2 arms), sponsored by Chiesi Farmaceutici S.p.A. Primary endpoint: Fractional exhaled nitric oxide at last visit of each treatment period. Started Mar 2008; status: terminated.
02
Drugs
beclometasone dipropionate + formoterolsalbutamol
03
Conditions
asthma
Beyond the preview
Go deeper on 2007-004377-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004377-26.